This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kilby, J. M.
Right arrow Articles by Saag, M. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kilby, J. M.
Right arrow Articles by Saag, M. S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2000, p. 2672-2678, Vol. 44, No. 10
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Safety and Pharmacokinetics of Once-Daily Regimens of Soft-Gel Capsule Saquinavir plus Minidose Ritonavir in Human Immunodeficiency Virus-Negative Adults

J. Michael Kilby,1 Greg Sfakianos,1 Nick Gizzi,2 Peggy Siemon-Hryczyk,2 Eric Ehrensing,1 Charles Oo,2 Neil Buss,3 and Michael S. Saag1,*

Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama1; Roche Laboratories, Nutley, New Jersey2; and F. Hoffmann-La Roche, Basel, Switzerland3

Received 20 December 1999/Returned for modification 16 April 2000/Accepted 20 July 2000

Human immunodeficiency virus type 1 (HIV-1) protease inhibitors have dramatically improved treatment options for HIV infection, but frequent dosing may impact adherence to highly active antiretroviral treatment regimens (HAART). Previous studies demonstrated that combined therapy with ritonavir and saquinavir allows a decrease in frequency of saquinavir dosing to twice daily. In this study, we evaluated the safety and pharmacokinetics of combining once-daily doses of the soft-gel capsule (SGC) formulation of saquinavir (saquinavir-SGC) and minidose ritonavir. Forty-four healthy HIV-negative volunteers were randomized into groups receiving once-daily doses of saquinavir-SGC (1,200 to 1,800 mg) plus ritonavir (100 to 200 mg) or a control group receiving only saquinavir-SGC (1,200 mg) three times daily. Saquinavir-SGC alone and saquinavir-SGC-ritonavir combinations were generally well tolerated, and there were no safety concerns. Addition of ritonavir (100 mg) to saquinavir-SGC (1,200 to 1,800 mg/day) increased the area under the concentration-time curve (AUC) for saquinavir severalfold, and the intersubject peak concentration in plasma and AUC variability were reduced compared to those achieved with saquinavir-SGC alone (3,600 mg/day), while trough saquinavir levels (24 h post-dose) were substantially higher than the 90% inhibitory concentration calculated from HIV-1 clinical isolates. Neither increasing the saquinavir-SGC dose to higher than 1,600 mg nor increasing ritonavir from 100 to 200 mg appeared to further enhance the AUC. These results suggest that an all once-daily HAART regimen, utilizing saquinavir-SGC plus a more tolerable low dose of ritonavir, may be feasible. Studies of once-daily saquinavir-SGC (1,600 mg) in combination with ritonavir (100 mg) in HIV-infected patients are underway.

* Corresponding author. Mailing address: UAB 1917 Clinic, 908 20th Street South, Birmingham, AL 35294. Phone: (205) 934-7349. Fax: (205) 934-8490. E-mail: msaag{at}uab.edu.

Antimicrobial Agents and Chemotherapy, October 2000, p. 2672-2678, Vol. 44, No. 10
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Huang, F., Koenen-Bergmann, M., MacGregor, T. R., Ring, A., Hattox, S., Robinson, P. (2008). Pharmacokinetic and Safety Evaluation of BILR 355, a Second-Generation Nonnucleoside Reverse Transcriptase Inhibitor, in Healthy Volunteers. Antimicrob. Agents Chemother. 52: 4300-4307 [Abstract] [Full Text]  
  • Marin-Niebla, A., Lopez-Cortes, L. F., Ruiz-Valderas, R., Viciana, P., Mata, R., Gutierrez, A., Pascual, R., Rodriguez, M. (2007). Clinical and Pharmacokinetic Data Support Once-Daily Low-Dose Boosted Saquinavir (1,200 Milligrams Saquinavir with 100 Milligrams Ritonavir) in Treatment-Naive or Limited Protease Inhibitor-Experienced Human Immunodeficiency Virus-Infected Patients. Antimicrob. Agents Chemother. 51: 2035-2042 [Abstract] [Full Text]  
  • von Hentig, N., Muller, A., Rottmann, C., Wolf, T., Lutz, T., Klauke, S., Kurowski, M., Oertel, B., Dauer, B., Harder, S., Staszewski, S. (2007). Pharmacokinetics of Saquinavir, Atazanavir, and Ritonavir in a Twice-Daily Boosted Double-Protease Inhibitor Regimen. Antimicrob. Agents Chemother. 51: 1431-1439 [Abstract] [Full Text]  
  • Ruane, P. J., Luber, A. D., Wire, M. B., Lou, Y., Shelton, M. J., Lancaster, C. T., Pappa, K. A., COL10053 Study Team, (2007). Plasma Amprenavir Pharmacokinetics and Tolerability following Administration of 1,400 Milligrams of Fosamprenavir Once Daily in Combination with either 100 or 200 Milligrams of Ritonavir in Healthy Volunteers. Antimicrob. Agents Chemother. 51: 560-565 [Abstract] [Full Text]  
  • Shelton, M. J., Wire, M. B., Lou, Y., Adamkiewicz, B., Min, S. S. (2006). Pharmacokinetic and Safety Evaluation of High-Dose Combinations of Fosamprenavir and Ritonavir. Antimicrob. Agents Chemother. 50: 928-934 [Abstract] [Full Text]  
  • Pulido, F., Ribera, E., Moreno, S., Munoz, A., Podzamczer, D., del Pozo, M. A., Rivero, A., Rodriguez, F., Sanjoaquin, I., Teira, R., Viciana, P., Villalonga, C., Antela, A., Carmena, J., Ena, J., Gonzalez, E., Kindelan, J. M., Mallolas, J., Marquez, M., Martinez, E. (2005). Once-daily antiretroviral therapy: Spanish Consensus Statement. J Antimicrob Chemother 56: 808-818 [Abstract] [Full Text]  
  • Boffito, M., Maitland, D., Dickinson, L., Back, D., Hill, A., Fletcher, C., Moyle, G., Nelson, M., Gazzard, B., Pozniak, A. (2005). Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily. J Antimicrob Chemother 55: 542-545 [Abstract] [Full Text]  
  • Autar, R. S., Ananworanich, J., Apateerapong, W., Sankote, J., Hill, A., Hirschel, B., Cooper, D., Lange, J., Phanuphak, P., Ruxrungtham, K., Burger, D. (2004). Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily. J Antimicrob Chemother 54: 785-790 [Abstract] [Full Text]  
  • Mouly, S. J., Paine, M. F., Watkins, P. B. (2004). Contributions of CYP3A4, P-glycoprotein, and Serum Protein Binding to the Intestinal First-Pass Extraction of Saquinavir. J. Pharmacol. Exp. Ther. 308: 941-948 [Abstract] [Full Text]  
  • Shelton, M. J., Cloen, D., DiFrancesco, R., Berenson, C. S., Esch, A., de Caprariis, P. J., Palic, B., Schur, J. L., Bugge, C. J. L., Ljungqvist, A., Espinosa, O., Hewitt, R. G. (2004). The Effects of Once-Daily Saquinavir/Minidose Ritonavir on the Pharmacokinetics of Methadone. J Clin Pharmacol 44: 293-304 [Abstract] [Full Text]  
  • Goujard, C., Vincent, I., Meynard, J.-L., Choudet, N., Bollens, D., Rousseau, C., Demarles, D., Gillotin, C., Bidault, R., Taburet, A.-M. (2003). Steady-State Pharmacokinetics of Amprenavir Coadministered with Ritonavir in Human Immunodeficiency Virus Type 1-Infected Patients. Antimicrob. Agents Chemother. 47: 118-123 [Abstract] [Full Text]  
  • Piliero, P. J. (2003). Early Factors in Successful Anti-HIV Treatment. J Int Assoc Physicians AIDS Care (Chic Ill) 2: 10-20 [Abstract]  
  • Lu, J.-F., Blaschke, T. F., Flexner, C., Rosenkranz, S. L., Sheiner, L. B. (2002). Model-based Analysis of the Pharmacokinetic Interactions Between Ritonavir, Nelfinavir, and Saquinavir after Simultaneous and Staggered Oral Administration. Drug Metab. Dispos. 30: 1455-1461 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»